Cadila seeks regulatory approval for COVID-19 drug
Indian drugmaker Cadila Healthcare Ltd said on Monday it would seek local regulatory approval to treat COVID-19 patients.
By Reuters | Updated:
Indian drugmaker Cadila Healthcare Ltd said on Monday it would seek local regulatory approval to treat COVID-19 patients with an already approved Hepatitis C drug, following promising interim results from a late-stage trial.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
Related Articles
No IIT, No MIT: After facing financial crisis during COVID-19, a 19-year-old is now earning Rs 1 crore by selling courses2026-06-24T03:48:14Z- India's private investment gains overtakes government share post-COVID: Report2026-06-22T12:31:05Z
- Did Joe Biden’s ex-medical advisor Fauci fund China’s Wuhan Lab research behind Covid-19 outbreak? Tulsi Gabbard’s final act with ‘never-before-seen’ documents reveals explosive claims2026-06-20T05:15:58Z
ADVERTISEMENT
